37 results
Summary of characteristics of Antianginal Drugs

DRUG CLASS, ADVERSE EFFECTS 
 AND DRUG 
INTERACTIONS 

#Antianginal #Medications #Cardiology
#Medications #Cardiology ... #Pharmacology # ... Management #Therapy
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
and recommended therapy ... resynchronization therapy ... CHF #Congestive #HeartFailure ... ACCAHA #Algorithm #Management ... #Cardiology
Therapy for AL Amyloidosis 2019 
 - Antibodies (Plasma cells) 
 - Proteasome Inhibitors 
 -
Therapy for AL Amyloidosis ... Antibodies (Plasma cells ... ALAmyloidosis #Therapy ... Medications #Therapies #Pharmacology ... #Management #Classes
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
areas Preferred Therapy ... Patients Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Treating Isospora belli ... Infection General Management ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
Antiarrhythmics - Vaughan Williams Classification
Class I (Ia, Ib, Ic) - Na+ Channel Blockade
 • Slows depolarization
Vaughan Williams Classification ... depolarization in fast AP cells ... VaughanWilliams #Classification ... #Classes #cardiology ... #pharmacology
Medications Used in Congestive Heart Failure

In CHF, the heart is failing as a pump; cardiac output
is chronic Drug therapy ... #Pharmacology #CHF ... Action #Congestive #HeartFailure ... #Cardiology #Preload
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
CD4 count <200 cells ... mm3 Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
days) Preferred Therapy ... or Alternative Therapy ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
BIII) Preferred Therapy ... /ml Preferred Therapy ... Prevention #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology